Dr Samik Basu | Director
Adaptimmune Llc

Dr Samik Basu, Director, Adaptimmune Llc

Dr. Samik Basu is currently the Director of Translational Sciences at Adaptimmune LLC.  Prior to joining Adaptimmune, Dr. Basu co-led preclinical development efforts for Pembrolizumab (Keytruda) at Merck Research Laboratories in Boston, Massachusetts.  He is a physician-scientist with 13 years of industry and academic experience in translational research, autoimmunity, and tumor immunology with prior roles at Merck, the National Institutes of Health, Albert Einstein College of Medicine, and the University of Pennsylvania.  Dr. Basu received his MD from Temple University and completed residency training in Clinical Pathology.


DC Co-conference Day 3 April 5 @ 09:10

Panel: Engineering CAR-T & TCR cells for cancer therapy

  • How can you additionally modify T-cells beyond the T cell receptor/ the CAR to behave in a more controlled and/or potent fashion?
  • The challenge of keeping the manufacturing process simple, whilst maintaining the effectiveness of the product
  • The use of molecular imaging to track CAR T cells: Where do they go in the body? Do they accumulate in the tumor?
  • Mitigating side effects: controlling neurotoxicity etc.
  • Biomarkers – Identifying patients that will respond to treatment
  • Combination strategies

back to speakers